{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-033744","form_type":"8-K","ticker":"MLAB","cik":"0000724004","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.917631+00:00","generated_at":"2026-05-30T04:05:50.038238+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"Mesa Labs Q2 revenue $57.8M (+8.8% YoY); core organic revs -2.8%; AOI margin 24.8%; net debt reduced by $7.4M","bullets":["Revenue $57.8M (+8.8% YoY); net income $3.4M ($0.63 diluted EPS) vs. prior year loss.","Non-GAAP AOI ex-unusual items $14.4M, margin 24.8% (up 210 bps); core organic revs declined 2.8%.","BPD division core organic growth 27.9% (strong capital equipment); CG declined 26.5% (China/LDT headwinds).","Repaid $7.4M debt in Q2; Net Leverage Ratio improved to 3.26, targeting below 3.0x.","GKE acquisition (closed late 2023) contributed 11% revenue growth, ahead of initial expectations."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-033744","json":"https://secwatch.observer/filing/0001437749-24-033744.json","markdown":"https://secwatch.observer/filing/0001437749-24-033744.md","text":"https://secwatch.observer/filing/0001437749-24-033744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/724004/000143774924033744/0001437749-24-033744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/724004/000143774924033744/mlab20241105_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:05:50.038238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}